JP2016539929A5 - - Google Patents

Download PDF

Info

Publication number
JP2016539929A5
JP2016539929A5 JP2016525990A JP2016525990A JP2016539929A5 JP 2016539929 A5 JP2016539929 A5 JP 2016539929A5 JP 2016525990 A JP2016525990 A JP 2016525990A JP 2016525990 A JP2016525990 A JP 2016525990A JP 2016539929 A5 JP2016539929 A5 JP 2016539929A5
Authority
JP
Japan
Prior art keywords
cells
cell
aapc
polyclonal
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016525990A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016539929A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/062191 external-priority patent/WO2015061694A2/en
Publication of JP2016539929A publication Critical patent/JP2016539929A/ja
Publication of JP2016539929A5 publication Critical patent/JP2016539929A5/ja
Pending legal-status Critical Current

Links

JP2016525990A 2013-10-25 2014-10-24 免疫療法のためのポリクローナルγδＴ細胞 Pending JP2016539929A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361895626P 2013-10-25 2013-10-25
US61/895,626 2013-10-25
PCT/US2014/062191 WO2015061694A2 (en) 2013-10-25 2014-10-24 Polyclonal gamma delta t cells for immunotherapy

Publications (2)

Publication Number Publication Date
JP2016539929A JP2016539929A (ja) 2016-12-22
JP2016539929A5 true JP2016539929A5 (enExample) 2017-11-30

Family

ID=52993756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016525990A Pending JP2016539929A (ja) 2013-10-25 2014-10-24 免疫療法のためのポリクローナルγδＴ細胞

Country Status (8)

Country Link
US (3) US9907820B2 (enExample)
EP (1) EP3060059A4 (enExample)
JP (1) JP2016539929A (enExample)
KR (1) KR20160068960A (enExample)
CN (1) CN105848484A (enExample)
AU (2) AU2014339926B2 (enExample)
CA (1) CA2926859A1 (enExample)
WO (1) WO2015061694A2 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1814580T (pt) 2004-11-24 2016-11-11 Hutchinson Fred Cancer Res Métodos de utilização de il-21 para imunoterapia adotiva e identificação de antigénios tumorais
EP2997134B1 (en) 2013-05-14 2020-06-24 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
WO2014190273A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
CN106414748B (zh) 2014-02-14 2021-05-28 得克萨斯州大学系统董事会 嵌合抗原受体及制备方法
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
US10570186B2 (en) 2014-11-05 2020-02-25 Board Of Regents, The University Of Texas System Chimeric antigen receptors (CAR) to selectively target protein complexes
IL297773B2 (en) 2014-11-17 2024-07-01 Adicet Bio Inc Engineered gamma delta t-cells
US20220280564A1 (en) * 2014-11-21 2022-09-08 Immatics US, Inc. Methods for expanding t cells for the treatment of cancer and related malignancies
US10808230B2 (en) 2015-02-24 2020-10-20 Board Of Regents, The University Of Texas System Selection methods for genetically-modified T cells
US10570382B2 (en) 2015-03-11 2020-02-25 Board Of Regents, The University Of Texas System Transposase polypeptides and uses thereof
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
WO2016179684A1 (en) * 2015-05-11 2016-11-17 University Health Network Method for expansion of double negative regulatory t cells
AU2016262484B2 (en) * 2015-05-12 2021-10-21 Memorial Sloan Kettering Cancer Center Methods of treating Epstein-Barr Virus-associated lymphoproliferative disorders by T cell therapy
PL3307875T3 (pl) 2015-06-09 2022-08-01 Lymphact - Lymphocyte Activation Technologies, S.A. Sposoby wytwarzania limfocytów t tcr gamma delta+
EP3623468A1 (en) * 2015-06-09 2020-03-18 Lymphact - Lymphocyte Activation Technologies, S.A. Methods for the production of tcr gamma delta+ t cells
CN105112370B (zh) * 2015-08-25 2019-02-05 杭州优善生物科技有限公司 一种体外刺激外周血γδT细胞高效增殖的方法及其应用
JP7105188B2 (ja) * 2015-08-25 2022-07-22 ザ・ユー・エイ・ビー・リサーチ・フアンデーシヨン 幹細胞移植方法
WO2017048902A1 (en) 2015-09-15 2017-03-23 Board Of Regents, The University Of Texas System T-cell receptor (tcr)-binding antibodies and uses thereof
CN105624107B (zh) * 2015-09-21 2020-06-12 杭州优善生物科技有限公司 一种多种淋巴细胞亚群的扩增方法及其应用
EP3368075B1 (en) 2015-10-27 2020-01-29 Board of Regents, The University of Texas System Chimeric antigen receptor molecules and uses thereof
KR20250093576A (ko) 2015-10-30 2025-06-24 캔써 리서치 테크놀로지 리미티드 비-조혈조직에 상재하는 γδ Ｔ 세포의 증식 및 이들 세포의 용도
AU2017261804A1 (en) * 2016-05-12 2018-11-29 Adicet Therapeutics, Inc. Methods for selective expansion of γδ T-cell populations and compositions thereof
EP3532078A4 (en) * 2016-10-31 2020-06-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. ARTIFICIAL ANTI-PRESENTING CELLS FOR THE EXPANSION OF IMMUNE CELLS FOR IMMUNOTHERAPY
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
EP3580331B1 (en) * 2017-02-08 2022-06-01 Agency For Science, Technology And Research Gamma delta t cells and a method of augmenting the tumoricidal activity of the same
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
GB201707048D0 (en) * 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
CN109337872B (zh) * 2017-07-27 2023-06-23 上海细胞治疗研究院 高效扩增car-t细胞的人工抗原递呈细胞及其用途
WO2019053272A1 (en) * 2017-09-15 2019-03-21 King's College London COMPOSITIONS AND METHODS FOR IMPROVING T GAMMA DELTA LYMPHOCYTES IN INTESTINE
CN107794269A (zh) * 2017-09-30 2018-03-13 成都美杰赛尔生物科技有限公司 促进基因编辑t细胞活化及扩增的生物膜、制法及应用
TWI687227B (zh) * 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
JP7227630B2 (ja) 2017-10-12 2023-02-22 マックマスター ユニバーシティー Ｙ１８２ｔ突然変異を有するｔ細胞－抗原カプラおよびその方法ならびに使用
AU2018370120C1 (en) 2017-11-15 2024-05-30 Adicet Therapeutics, Inc. Methods for selective expansion of d3 yd T-cell populations and compositions thereof
CN108588023B (zh) * 2018-05-09 2020-02-14 河北森朗生物科技有限公司 一种生产嵌合抗原受体修饰的γδT细胞的方法
US10640562B2 (en) 2018-07-17 2020-05-05 Mcmaster University T cell-antigen coupler with various construct optimizations
CA3113409A1 (en) * 2018-09-19 2020-03-26 Lava Therapeutics B.V. Dual acting cd1d immunoglobulin
WO2020065584A1 (en) * 2018-09-27 2020-04-02 Phosphogam, Inc. Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells
AU2019354395A1 (en) * 2018-10-01 2021-05-06 Adicet Therapeutics, Inc. Compositions and methods regarding engineered and non-engineered γδ -T cells for treatment of solid tumors
KR20210070330A (ko) 2018-10-01 2021-06-14 아디셋 바이오, 인크. 혈액 종양의 치료를 위한 조작된 및 비-조작된 γδ-T 세포에 관한 조성물 및 방법
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
WO2020170260A1 (en) * 2019-02-24 2020-08-27 Gamida-Cell Ltd. Method of homing and retention of gammadelta t cells for generating cell compositions for use in therapy
PE20220763A1 (es) * 2019-05-08 2022-05-16 Janssen Biotech Inc Materiales y metodos para modular la inmunidad mediada por celulas t
WO2021016652A1 (en) * 2019-07-29 2021-02-04 The University Of Melbourne METHODS AND COMPOSITIONS FOR MONITORING, TREATING AND PREVENTING CMV INFECTION OR GRAFT REJECTION USING γδ T-CELLS
EP4028413A1 (en) 2019-09-10 2022-07-20 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
CN111647070B (zh) * 2020-06-17 2022-06-03 深圳豪石生物科技有限公司 T细胞受体或其抗原结合片段及应用
EP4196133A4 (en) * 2020-08-12 2024-09-04 University of Central Florida Research Foundation, Inc. METHODS AND COMPOSITIONS FOR STIMULATING GAMMA DELTA T CELLS
KR20240037892A (ko) 2021-06-01 2024-03-22 트리움비라 이뮤놀로직스 유에스에이, 인크. 클라우딘 18.2 t 세포-항원 커플러 및 이의 용도
US20230117388A1 (en) * 2021-10-20 2023-04-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods and materials for expanding tumor infiltrating gamma-delta t cells
US20250017966A1 (en) * 2021-11-18 2025-01-16 Regents Of The University Of Minnesota Large-scale expansion of engineered human gamma delta t cells
EP4183871A1 (en) 2021-11-23 2023-05-24 Université d'Aix-Marseille Process for preparing a composition comprising a combined cell population
IL314940A (en) 2022-02-16 2024-10-01 Priothera Sas Methods of treatment with car cells in combination with s1p receptor modulators
KR20240170816A (ko) * 2022-04-04 2024-12-04 감마델타 테라퓨틱스 엘티디 신규의 유전자 아모링
CN114645022B (zh) * 2022-05-13 2022-09-02 首都医科大学宣武医院 靶向CD5的CAR-γ δ T细胞及其制备方法与应用
WO2025046256A1 (en) 2023-08-31 2025-03-06 Universite D'aix-Marseille Process for preparing a composition comprising a combined cell population
CN118064364B (zh) * 2024-04-19 2024-07-05 赛德特生物制药有限公司 一种γδT细胞的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125884A0 (en) 1996-03-04 1999-04-11 Targeted Genetics Corp Modified rapid expansion methods ("modified-rem") for in vitro propagation of t lymphocytes
CA2360046A1 (en) * 1999-01-28 2000-08-03 Lawrence S. Lamb, Jr. In vitro activated gamma delta lymphocytes
US7638325B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
WO2005118788A2 (en) 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
EP2079830B1 (en) * 2006-10-04 2016-08-17 Janssen Pharmaceutica NV Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
DK2311470T3 (en) * 2008-07-01 2015-08-17 Medinet Co Ltd A method for simultaneous induction of CTLs and gamma delta T cells
WO2010030947A1 (en) 2008-09-11 2010-03-18 University Of Florida Research Foundation, Inc. System and method for producing t cells
WO2012156958A2 (en) 2011-05-19 2012-11-22 Instituto De Medicina Molecular Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof
US20120321666A1 (en) 2011-05-23 2012-12-20 Cooper Laurence J N T cell therapy for b cell lymphoma
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla

Similar Documents

Publication Publication Date Title
JP2016539929A5 (enExample)
Cerwenka et al. Natural killer cell memory in infection, inflammation and cancer
Becker et al. Selection and expansion of natural killer cells for NK cell-based immunotherapy
Butler et al. Human cell‐based artificial antigen‐presenting cells for cancer immunotherapy
Themeli et al. New cell sources for T cell engineering and adoptive immunotherapy
JP7002769B2 (ja) ウイルス特異的ｔ細胞の活性化および拡大のためのプラットフォーム
JP7584414B2 (ja) 複数の免疫細胞タイプの同時増殖のための方法、関連する組成物および癌免疫療法におけるそれらの使用
Bae et al. Activation of NKT cells in an anti-PD-1–resistant tumor model enhances antitumor immunity by reinvigorating exhausted CD8 T cells
Ames et al. Advantages and clinical applications of natural killer cells in cancer immunotherapy
Putnam et al. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation
Dianat‐Moghadam et al. Natural killer cell–based immunotherapy: From transplantation toward targeting cancer stem cells
Berger et al. Adoptive transfer of virus-specific and tumor-specific T cell immunity
ES2877108T3 (es) Activación de linfocitos infiltrantes de médula en condiciones hipóxicas alternantes con normóxicas
CN107002039B (zh) 使用t细胞用于培养自然杀伤细胞的方法
Wang et al. CMVpp65 vaccine enhances the antitumor efficacy of adoptively transferred CD19-redirected CMV-specific T cells
JP2016509840A5 (enExample)
JP2018502114A5 (enExample)
EP3138905A1 (en) Method for natural killer cell expansion
CN111566201A (zh) 使用用于表达嵌合抗原受体(car)或转基因t细胞受体(tcr)的病毒载体转导细胞的方法
JP2017533706A5 (enExample)
RU2017111300A (ru) Центральные т-клетки памяти для адоптивной т-клеточной терапии
JP2018522072A5 (enExample)
JP2021505604A5 (enExample)
Giang et al. Nanoparticles engineered as artificial antigen-presenting cells induce human CD4+ and CD8+ Tregs that are functional in humanized mice
Lizana-Vasquez et al. The application of autologous cancer immunotherapies in the age of memory-NK cells